A Christmas review:
1. Biogen Inc. (BGEN): The biotechnology company was raised to
''strong buy'' from ''outperform'' by analyst Douglas D. Lind at
Morgan Stanley Dean Witter. Lind expects the stock price to rise
to $90. Biogen fell 7 1/16 to 79 13/16.
2. Princeton, New Jersey, Dec. 24 (Bloomberg Data) -- Biogen Inc. (BGEN US)
was maintained ''market outperform'' by analyst May-Kin Ho at Goldman, Sachs &
Co.
3. Princeton, New Jersey, Dec. 24 (Bloomberg Data) -- Biogen Inc. (BGEN US)
was rated ''buy'' in new coverage by analyst Jay B. Silverman at BancBoston
Robertson Stephens. The 12-month target price is $100.00 per share.
4. Princeton, New Jersey, Dec. 24 (Bloomberg Data) -- Biogen Inc. (BGEN US)
was maintained ''buy'' by analyst Meirav Chovav at Salomon Smith Barney.
Chovav raised his price target to $92.00 from $80.00 per share.
5. Princeton, New Jersey, Dec. 24 (Bloomberg Data) -- Biogen Inc. (BGEN US)
was maintained ''buy'' by analyst C. Anthony Butler at Lehman Brothers.
The price target is $100.00 per share.
6. Princeton, New Jersey, Dec. 24 (Bloomberg Data) -- Biogen Inc. (BGEN US)
was maintained ''buy'' by analyst Jeffrey R. Swarz at Credit Suisse First
Boston Inc. The price target is $90.00 per share.
7. Hambrick and Quist also mainted Bgen at a buy.
8. Dec 24 (Reuters) - EVEREN Securities said Thursday it viewed the sell-off in shares of Biogen Inc. (Nasdaq:BGEN - news) as a buying opportunity and would be ''aggressively'' purchasing shares at current levels.
-- Biogen shares fell sharply Wednesday after the surprise news that James Tobin would resign as chief executive officer. The stock closed at 79-13 on Nasdaq, down 7-1/16. It was down as much as 16-2/16 during the day.
-- EVEREN says Biogen is a profitable biotechnology company that is marketing the leading treatment for multiple sclerosis, receives royalty revenues from four compounds, and has several promising products in clinical development.
-- ''We view investors as overreacting to the news, as it blindsided everybody on the street, and would be aggressively buying shares,'' EVEREN said in a report.
-- It has the stock rated outperform on both an intermediate and long-term basis
9. Merrill on Monday?
I believe this bodes well for Monday. Merry Christmas everyone. |
